You are here

Home
  • Overview
  • Registration & Abstract
  • Agenda
  • Keynote Speaker
  • Sponsors
  • Contact
  • Location
November
01
Friday
  • 8:30 AM
  • Vantage Venues, 27th Floor
    150 King Street West
    Toronto, Ontario

WELCOME!

Welcome to the 2nd Lung Oncology Research website. This annual event celebrates our achievements in basic and clinical research. UHN Lung Site Research Day is designed for our group to share, update, and discuss ongoing lung cancer research across the entire multi-disciplinary spectrum with participation from researchers, clinicians, and trainees. 

Our keynote speaker for this year is Dr Marc Ladanyi, Chief of the Molecular Diagnostics Service in the Department of Pathology at Memorial Sloan-Kettering Cancer Center.

This year, Research Day will be held on Friday, November 01, at the Vantage Venues, 27th floor located at 150 King Street West in downtown Toronto.
Trainees (i.e., clinical fellows, postdoctoral fellows, residents, & graduate students) currently working under the supervision of a Principal Investigator in the lung site are invited to submit an abstract for an oral presentation or a poster. Abstracts submitted to international or national meetings over the past year are welcome. There will be Awards for the best clinical and basic science presentations.

Participation at the Research Day is free and we encourage everyone to register as soon as possible.  

If you plan to submit an abstract, please register and then email your abstract to Fatemeh Zaeimi, Fatemeh.Zaeimi@uhn.ca

Please mark your calendars for November 01, 2019 and we look forward to seeing you there!

IMPORTANT DATES:
Abstract Submission Deadline:  Monday, September 30, 2019 at 4:00 p.m. (no late submissions will be accepted)
Registration Closes:  Friday, October 4, 2019 at 4:00 pm.

Online registration is mandatory for all presenters and general attendees.

 

 

 

REGISTRATION

Registration for the PMCC 2nd Annual Lung Oncology Research Day - 2019 is now open.  You must register in advance if you wish to attend, as we need to plan for seating, catering, printing of programs, etc.  The deadline to register is Friday, October 4, 2019 at 4:00 pm.

ABSTRACT

Abstract submissions are due by Monday, September 30, 2019 at 4:00 p.m. No late submissions will be accepted.

Trainees (i.e., clinical fellows, postdoctoral fellows, residents, & graduate students) currently working under the supervision of a Principal Investigator in the lung site are invited are invited to submit an abstract for an oral presentation.  If you wish to submit a first-authored abstract, please note that abstract submission and registration are part of the same process.  Please register first and later email your abstract to Fatemeh.Zaeimi@uhn.ca when your abstract is ready for submission. 

Abstracts submitted to international or national meetings over the past year are welcome. Prizes will be awarded for the best clinical and basic science presentations.

Submission Instructions:

Abstract:  Your abstract must not exceed a maximum of 2000 characters including spaces (approximately 300 words).

Abstract Format:  Abstracts MUST be in a standardized format with the following subheadings: Hypothesis, Materials and Methods, Results, and Conclusion.

Abstract Authors:  Please type in all names using the first and middle initials followed by the author's last name. A comma should separate author names and the final name should be followed by a period.
For example:  SR Wilson, MK O'Reilly, JP Leduc, and BA Bell.

Affiliations:  Please type in all affiliations including your PMCC affiliation.  A semi-colon should separate each affiliation and the final affiliation should be followed by a period.

If you have any questions, please contact: Fatemeh.Zaeimi@uhn.ca
 

Time Program Session Chair
08:00 Registration and Breakfast  
08:30 – 08:35 Welcome and  Opening Remarks- Dr. Marc de Perrot  
08:35 – 09:45 Session I – Targeted Therapy
  • Dr. Frances Shepherd:  Targeted therapy for non-small cell lung cancer
  • Dr. Erin Stewart  - “Genomic Profiling of Liquid Biopsies during progression on 2nd/3rd generation EGFR and ALK TKIs to Identify Novel Mechanisms of Resistance”
  • Dr. Aline Fares – “Genomic Landscape of EGFR/ALK Wild-Type Lung Adenocarcinomas in Never-Smokers and Importance of Epithelial-Mesenchymal-Transition”
  • Dr. Sebastiao Martins-Filho - Neuroendocrine transformation of EGFR-mutated lung adenocarcinoma
  • Dr. Prodipto Pal – “Identification of Neuroendocrine Transformation in Anaplastic Lymphoma Kinase Rearranged (ALK+) Tumors After Tyrosine Kinase Inhibitors”

 
End of session Discussion

 Dr. Adrian Sacher
09.45 – 10:00 Coffee Break  
10:00 – 11:00 Session II – Genomics and Immunotherapy
  • Dr. Geoffrey Liu - Cell free DNA and circulating tumour cell analysis in lung cancer”
  • Dr. Sally Lau – “Dominant Circulating Myeloid Populations Are Associated with Poor Response in NSCLC Treated with 1st Line PD-1 Monotherapy”
  • Dr. Sandy Lou – “Technical validation of PD-L1 22C3 immunohistochemistry for cell block preparations: Cyto-histological concordance and fixation effects”

 
End of session discussion

 Dr. Benjamin Lok
11:00-12:00 Keynote Speaker – Dr. Marc Ladanyi
“Clinical Genomic Testing of Lung Cancer Patients to Guide Targeted and Immune Therapies”
 
 
 
 
 		  
Noon -13:00 Lunch  
13:00 – 14:10 Session III – Translational Model
  • Dr. Jonathan Yeung - Patient derived organoid culture in esophageal adenocarcinoma.  
  • Dr. Kelsie Thu – “Development of an in Vivo Platform to Identify Novel Mechanisms Governing Lung Cancer Response to Immunotherapy”
  • Dr. Erin Stewart – “Tumor-Stromal Microenvironment Interactions in a PDX Model of EGFR TKI Drug Tolerance”
  • Dr. Andrea Fung – “Genomic profiling in non-small cell lung cancer: Updates on LUNGS1 and LUNGS2”

 
End of session discussion

 Dr. Tom Waddell
14:10 – 14:20 Coffee Break  
14:20 – 15:20 Session IV – Radiation Interaction
  • Dr. Patrick Cheung – “SBRT for pulmonary mets and lymphadenopathy”
  • Dr. Michael Tjong – “Safety of Palliative Radiotherapy and Immune Checkpoint Inhibitors in Patients with Metastatic Non-Small Cell Lung Cancer”
  • Dr. John Cho – “A Feasibility Study Evaluating Surgery for Mesothelioma After Radiation Therapy using Extensive Pleural Resection – SMARTER”
  • Dr. Marc de Perrot - “The role of radiation to generate an in situ vaccination”

 
End of session discussion

 Dr. Alex Sun
15:20-15:30 Coffee Break  
15:30 – 16:30 Session V – Technology & Imaging
  • Dr. Kazuhiro Yasufuku – “Trans-bronchial Therapeutics of Lung Cancer - What is on the Horizon”
  • Dr. Kasia Czarnecka: Diagnostic Approaches Suspected IO Progression/ Pseudoprogression and What/When to Re-biopsy for TT Progression
  • Zahra Afraz – “CT-guided lung biopsy: operator impact on needle dwell time, radiation dose and complication rate”
  • Meghan Lambie – “Preclinical models to investigate radiosensitizers in radioresistant squamous cancers”

End of session discussion

 Dr. Andrea Bezjak
16:30 Awards Ceremony & Recognition  

Dr. Marc Ladanyi, MD
Dr. Ladanyi is a pathologist and the Chief of the Molecular Diagnostics Service in the Department of Pathology at Memorial Sloan-Kettering Cancer Center, where he is also the William Ruane Chair in Molecular Oncology. His research focuses on the genetics, genomics and molecular pathogenesis of cancers.
 		  

CONTACT

If you have any comments and inquiries regarding Lung Oncology Research Day please contact Fatemeh.Zaeimi@uhn.ca

 

LOCATION

The 2nd Annual Lung Oncology Research Day will be held at the Vantage Venues-150 King Street West, 27th Floor.

Friday, November 1, 2019 - 08:30